Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia

Prostate

Volumn 71, Issue 15, 2011, Pages 1701-1709

  Robert, Grégoire ^a,b,c   Smit, Frank ^d   Hessels, Daphne ^d   Jannink, Sander ^d   Karthaus, Herbert F M ^e   Aalders, Tilly ^a   Jansen, Kees ^a   De La Taille, Alexandre ^c   Mulders, Peter F ^a   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL PELLEGRIN   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d NovioGendix   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

benign prostatic hyperplasia; biomarker; inflammation; risk factor

Indexed keywords

BIOLOGICAL MARKER; CD19 ANTIGEN; CD28 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CXCL11 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN ICOS; RANTES; UNCLASSIFIED DRUG;

ARTICLE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATIC INFLAMMATION; RADICAL RETROPUBIC PROSTATECTOMY; SCORING SYSTEM; TRANSURETHRAL RESECTION; URINALYSIS; URINE FLOW RATE;

BIOLOGICAL MARKERS; CTLA-4 ANTIGEN; HISTOCYTOCHEMISTRY; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PROSTATITIS; RECEPTORS, CCR7; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 80053204210     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21387     Document Type: Article

References (28)

1. Garraway WM, Collins GN, Lee RJ:, High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338 (8765): 469-471.
2. Lee KL, Peehl DM:, Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004; 172 (5 Pt 1): 1784-1791. (Pubitemid 39363056)
3. Kramer G, Mitteregger D, Marberger M:, Is benign prostatic hyperplasia (BPH) an immune inflammatory disease ? Eur Urol 2007; 51 (5): 1202-1216. (Pubitemid 46436310)
4. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A:, Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003; 43 (2): 164-175. (Pubitemid 36221971)
5. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS:, The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE Trial. Eur Urol 2008; 54 (6): 1379-1384.
6. Minnery CH, Getzenberg RH:, Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. J Urol 2005; 174 (1): 375-379. (Pubitemid 40825761)
7. Di Silverio F, Bosman C, Salvatori M, Albanesi L, Proietti Pannunzi L, Ciccariello M, Cardi A, Salvatori G, Sciarra A:, Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005; 47 (1): 72-78 (discussion 78-79).
8. Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN:, Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: A prospective, randomized, double-blind, placebo-controlled study. Urology 2008; 72 (4): 813-816.
9. Buck AC:, Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004; 172 (5 Pt 1): 1792-1799. (Pubitemid 39363057)
10. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM:, Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2010; 171 (5): 571-582.
11. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L:, Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007; 51 (2): 524-533 (discussion 533). (Pubitemid 44937795)
12. Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, Fraccica G, Gangemi S:, Malondialdehyde in benign prostate hypertrophy: A useful marker ? Mediators Inflamm 2003; 12 (2): 127-128. (Pubitemid 36783253)
13. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J:, Inflammation in benign prostatic hyperplasia: Correlation with prostate specific antigen value. J Urol 1997; 157 (4): 1301-1303. (Pubitemid 27130803)
14. Goulter AB, Harmer DW, Clark KL:, Evaluation of low density array technology for quantitative parallel measurement of multiple genes in human tissue. BMC Genomics 2006; 7: 34.
15. Pfaffl MW:, A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29 (9): e45.
16. Bierhoff E, Walljasper U, Hofmann D, Vogel J, Wernert N, Pfeifer U:, Morphological analogies of fetal prostate stroma and stromal nodules in BPH. Prostate 1997; 31 (4): 234-240. (Pubitemid 27247314)
17. Fujikawa S, Matsuura H, Kanai M, Fumino M, Ishii K, Arima K, Shiraishi T, Sugimura Y:, Natural history of human prostate gland: Morphometric and histopathological analysis of Japanese men. Prostate 2005; 65 (4): 355-364. (Pubitemid 41759968)
18. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP:, Evaluation of prostatitis in autopsied prostates-Is chronic inflammation more associated with benign prostatic hyperplasia or cancer ? J Urol 2008; 179 (5): 1736-1740.
19. Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, Maille P, Allory Y, de la Taille A:, Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69 (16): 1774-1780.
20. Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A:, Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia ? Eur Urol Suppl 2009; 8 (13): 879-886.
21. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE:, Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66 (1): 96-107.
22. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, Paikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C, Marberger M:, Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83 (8): 1131-1146. (Pubitemid 37013048)
23. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M:, Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52 (1): 43-58. (Pubitemid 34553191)
24. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ:, Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56 (3): 171-182. (Pubitemid 36918167)
25. Palmer DH, Hussain SA, Ganesan R, Cooke PW, Wallace DM, Young LS, James ND:, CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule. Oncol Rep 2004; 12 (4): 679-682.
26. Moghaddami M, Cohen P, Stapleton AM, Brown MP:, CD40 is not detected on human prostate cancer cells by immunohistologic techniques. Urology 2001; 57 (3): 573-578. (Pubitemid 32193003)
27. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P:, Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 2009; 106 (8): 2729-2734.
28. Robert G, Descazeaud A, de la Taille A:, Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Who are the high-risk patients and what are the best treatment options ? Curr Opin Urol 2011; 21 (1): 42-48.